|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2002; 39:70-78 © 2002 by the American College of Cardiology Foundation |
* Stanford University Medical School, Stanford, California, USA
University of Texas Medical School, Houston, Texas, USA
Merck & Co., West Point, Pennsylvania, USA
Manuscript received November 10, 2000; revised manuscript received August 3, 2001, accepted October 11, 2001.
* Reprint requests and correspondence: Dr. Michael B. Fowler, Falk-CVRC 295, Stanford University Medical Center, Stanford, California 94305 USA.
mfowler{at}stanford.edu
OBJECTIVES: We sought to compare the neurohormonal responses and clinical effects of long-term, high-dose versus low-dose enalapril in patients with chronic heart failure (CHF).
BACKGROUND: Examination of neurohormonal and clinical responses in patients receiving different doses of angiotensin-converting enzyme (ACE) inhibitors may provide insight into the potential for additional suppression with angiotensin II (AT-II) or aldosterone antagonists.
METHODS: Seventy-five patients with CHF were randomized to receive either high-dose (40 mg/day, n = 37) or low-dose (5 mg/day, n = 38) enalapril over six months. The results from exercise testing, echocardiography, tissue-specific ACE activity and monthly pre- and post-enalapril neurohormonal levels were compared.
RESULTS: Despite greater intra-group improvements in plasma renin activity and serum aldosterone levels in the high-dose group, no statistically significant differences were observed between the two groups in all variables, except for serum ACE activity at the end of study. Elevated serum aldosterone and plasma AT-II levels were observed in 35% and 85% of patients, respectively, at 34 weeks, an inter-group difference that was not statistically significant. A trend toward higher levels of tissue-specific ACE activity in the high-dose group compared with the low-dose group at the end of study was observed (p = 0.054). A predefined composite end point of clinical events had a trend toward better improvement in the high-dose group.
CONCLUSIONS: This study could not demonstrate a difference between high- and low-dose enalapril in terms of serum aldosterone and plasma AT-II suppression, despite a dose-dependent reduction in serum ACE activity. Even at maximal doses of enalapril, elevated serum aldosterone and plasma AT-II levels were frequently observed.
| ||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Klotz, A.H. J. Danser, R. F. Foronjy, M. C. Oz, J. Wang, D. Mancini, J. D'Armiento, and D. Burkhoff The Impact of Angiotensin-Converting Enzyme Inhibitor Therapy on the Extracellular Collagen Matrix During Left Ventricular Assist Device Support in Patients With End-Stage Heart Failure J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1166 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. McNamara, R. Holubkov, L. Postava, K. Janosko, G. A. MacGowan, M. Mathier, S. Murali, A. M. Feldman, and B. London Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2019 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Gring and G. S. Francis A hard look at angiotensin receptor blockers in heart failure J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1841 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Roffman High-Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure Ann. Pharmacother., May 1, 2004; 38(5): 831 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jessup and S. Brozena Heart Failure N. Engl. J. Med., May 15, 2003; 348(20): 2007 - 2018. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Mehra, P. A. Uber, and G. S. Francis Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1606 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sato, K. Hayashi, M. Naruse, and T. Saruta Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy Hypertension, January 1, 2003; 41(1): 64 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.N. Doughty and N. Sharpe Optimization of ACE inhibitor therapy in heart failure Eur. Heart J., September 1, 2002; 23(17): 1322 - 1323. [Full Text] [PDF]
|
|
|
|
 |
|
 U. P. Jorde, T. Vittorio, S. D. Katz, P. C. Colombo, F. Latif, and T. H. Le Jemtel Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure Circulation, August 27, 2002; 106(9): 1055 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ACE-Inhibitor Dose Level Does Not Affect Neurohormonal Blockade in Heart Failure Journal Watch Cardiology, April 12, 2002; 2002(412): 5 - 5. [Full Text]
|
|
|
|
|
|
B. M. Massie Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much? J. Am. Coll. Cardiol., January 2, 2002; 39(1): 79 - 82. [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
